Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd / Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
ALLSCHWIL/BASEL, SWITZERLAND - 04 May 2010 - At today's Annual General Meeting
of Actelion Ltd (SIX: ATLN), shareholders approved all resolutions.
Shareholders approved the annual report, including the financial statements, for
the year 2009 and confirmed Ernst & Young to serve as the company's statutory
auditors for the year 2010.
The shareholders re-elected three Board members for a term of office of three
years. They are Mr. Werner Henrich, Mr. Armin Kessler and Mr. Jean Malo.
The Board comprises a total of ten members: Robert E. Cawthorn (Chairman),
Joseph C. Scodari (Vice-Chairman), Jean-Paul Clozel, Werner Henrich, Armin
Kessler, Jean Malo, Juhani Anttila, Carl Feldbaum, Michael Jacobi and Elias A.
Zerhouni.
The Annual General Meeting of Actelion took place in Basel on Tuesday, 04 May
2010. It was attended by 319 shareholders, representing 45'919'801 shares or
35.52% percent of the total outstanding shares.
###
Actelion Ltd.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer® through its own
subsidiaries in key markets worldwide, including the United States (based in
South San Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in innovative
science related to the endothelium - the single layer of cells separating every
blood vessel from the blood stream. Actelion's over 2,300 employees focus on
the discovery, development and marketing of innovative drugs for significant
unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange
(ticker symbol: ATLN).
For further information please contact:
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
Roland Haefeli
Vice President, Head of Investor Relations & Public
Affairs
+41 61 565 62 62
+1 650 624 69 36
http://www.actelion.com
[HUG#1411721]
--- End of Message ---
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland
ISIN: CH0010532478;
Press Release PDF: http://hugin.info/131801/R/1411721/364066.pdf
Unternehmensinformation / Kurzprofil:
Datum: 04.05.2010 - 16:01 Uhr
Sprache: Deutsch
News-ID 20242
Anzahl Zeichen: 0
contact information:
Town:
Allschwil
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 179 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
